TCM
TARS icon

Tang Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Tang Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.7M Buy
1,568,266
+379,642
+32% +$24.3M 4.48% 10
2026
Q1 		$83.4M Hold
1,188,624
– – 4.23% 12
2025
Q4 		$97.3M Sell
1,188,624
-1,266,173
-52% -$94.5M 4.81% 6
2025
Q3 		$146M Hold
2,454,797
– – 5.62% 1
2025
Q2 		$99.4M Hold
2,454,797
– – 5.03% 2
2025
Q1 		$126M Buy
2,454,797
+200,000
+9% +$9.89M 6.98% 1
2024
Q4 		$125M Hold
2,254,797
– – 8.26% 1
2024
Q3 		$74.2M Hold
2,254,797
– – 5.3% 2
2024
Q2 		$61.3M Hold
2,254,797
– – 6.24% 1
2024
Q1 		$82M Buy
2,254,797
+50,000
+2% +$1.47M 8.53% 1
2023
Q4 		$44.6M Buy
2,204,797
+64,211
+3% +$1.07M 4.13% 3
2023
Q3 		$38M Buy
2,140,586
+361,428
+20% +$6.4M 5.37% 1
2023
Q2 		$32.1M Sell
1,779,158
-255,000
-13% -$4.05M 4.73% 2
2023
Q1 		$25.6M Buy
2,034,158
+32,573
+2% +$476K 3.81% 5
2022
Q4 		$29.3M Sell
2,001,585
-88,271
-4% -$1.46M 4.26% 4
2022
Q3 		$35.8M Buy
2,089,856
+5,486
+0.3% +$87.1K 4.39% 4
2022
Q2 		$30.4M Buy
2,084,370
+1,784,370
+595% +$26.8M 4.62% 7
2022
Q1 		$5.05M Buy
+300,000
New +$5.57M 1.01% 29

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tang Capital Management's TARS Position: Q2 2026 in Review

Tang Capital Management increased its Tarsus Pharmaceuticals (TARS) stake by 32% in Q2 2026, buying an estimated $24.3M and bringing the position to 1,568,266 shares worth $98.7M. The position accounts for 4.48% of the portfolio, ranked #10.

Tang Capital Management first reported a position in TARS in Q1 2022 and has held it in 18 quarters since. The position peaked at $146M in Q3 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Tang Capital Management held 1,568,266 shares of Tarsus Pharmaceuticals worth $98.7M as of Q2 2026.
  • Tang Capital Management bought 379,642 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $24.3M.
  • Tarsus Pharmaceuticals made up 4.48% of Tang Capital Management's portfolio in Q2 2026, its #10 holding.
  • Tang Capital Management first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Tang Capital Management's Tarsus Pharmaceuticals position peaked at $146M in Q3 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.